AFT Crystawash reg’n in China and new licencing agreements

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969





27 March 2023
AFT gains first product registration in China with Crystawash Extend
and extends Maxigesic IV licensing

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces its achievement of
registration for sale of its long-lasting hand sanitiser Crystawash
®
Extend in China.

AFT also announces it has signed further new licence agreements for the intravenous
dose form of its Maxigesic pain relief medicine as it continues to build momentum in
its international business.

The Chinese National Medical Products Administration (NMPA) approved Crystawash
Extend – 24-hour long-lasting hand sanitiser which allows AFT to sell into retail stores in
mainland China. Crystawash Extend sanitises and protects against 99.99% of germs
for up to 24 hours. It is non-toxic & alcohol-free. AFT will commercialise this product
range within the next 6 to12 months into mainland China.

The privately owned Swiss pharmaceutical company Labatec has licensed the
intravenous form, Maxigesic IV
®
, in Switzerland. Labatec and AFT are aiming for
registration and launch of the medicine - a treatment for mild to moderate pain for
use post-operatively in hospitals when patients cannot take a medicine orally – in the
next 12 to 18 months.

Pharma Bavaria has extended its existing Maxigesic IV licence agreement in Latin
America to include Argentina and Paraguay in addition to the licences already
agreed with AFT for the medicine in Bolivia, Chile, Columbia, Ecuador, Peru, Uruguay.

The agreements build on launches of Maxigesic IV since the start of the year in the
Netherlands, Denmark, Sweden, Norway, and Finland.

AFT Managing Director Dr Hartley Atkinson said: “These licensing, registration and
distribution agreements and the recent launches will add to the growing momentum
we are seeing in the company’s international business.

“As a result of these launches and recent sales AFT will enter the new financial year
with Maxigesic sold in 61 countries in various dose forms, 15 more than where we were
in March 2022, although just short of our target of 63 countries. We are pleased with

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969

the progress we are making in realising the potential of our Maxigesic intellectual
property. Additionally, we are pleased to achieve our first product registration in
Mainland China and further registrations are pending.”

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

Released for and on behalf of AFT Pharmaceuticals by Malcolm Tubby, Chief Financial
Officer

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets, and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over the counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded, and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com
About Labatec
Labatec is a privately owned Swiss-based pharmaceutical company based out of
Geneva, Switzerland with an operational hub in Portugal. Labatec is present in the
Swiss market in addition to the Middle East North Africa markets, selling over 100
products in the Hospital and Speciality retail segments. For more information visit:
www.labatecpharma.com/
About Pharma Bavaria
Pharma Bavaria International Group distributes and promotes high-quality
pharmaceuticals with well-researched ingredients in more than 45 countries. With a
strong focus on growth regions such as the Middle East, Africa, South-East Asia, CIS
countries and other emerging economies Pharma Bavaria’s portfolio of prescription
medicines includes anti-infectives, analgesic/anti-allergic/anti-inflammatory, flu and
cold, gastroenterology, oncology, cardiology, and women’s healthcare brands and
is rounded off with a range of OTC products. For more information visit: www.pharma-
bavaria.com.